This is a multicenter, prospective, randomised, placebo-controlled study in patients with chronic heart failure with reduced ejection fraction (HFrEF), evaluating the effect of Shengxian Quyu Decoction versus placebo, given twice daily in addition to background regional standard of care therapy. The effect of Shengxian Quyu Decoctionon quality of life, symptoms and biomarkers will be evaluated.~The primary and secondary endpoints will be examined in subgroups determined by baseline variables reflecting demography, heart failure characteristics, Traditional Chinese Medicine syndrome type, diabetes status, kidney function, left ventricular ejection fraction, natriuretic peptide, and additional co-morbidities, concomitant medications, and others.
The purpose of this study is to conduct a multicenter, randomized clinical trial to evaluate the effect of Shengxian Quyu Decoction on quality of life , symptoms, and biomarkers in heart failure patients with reduced ejection fraction.